Back to Treatments

Treatment

Pembrolizumab (monotherapy)

1
Conditions
36
Trials
8,000
Participants
40%
Average Safety

Condition Evidence

Uterine cancer

36 trials · 8,000 participants

60% effectiveness · 40% safety
Pembrolizumab (monotherapy) | DFDA